Encelto™ (revakinagene taroretcel-lwey)

Encelto (revakinagene taroretcel-lwey) is covered one time per lifetime (one intravitreal implant per affected eye containing 200,000–440,000 allogeneic RPE cells expressing rhCNTF) for adults with idiopathic macular telangiectasia type 2 and is excluded for patients <18 years, those with neovascular/proliferative MacTel, BCVA worse than 54 ETDRS letters or 20/80 Snellen, or for non‑approved indications. Coverage requires documentation of diagnosis, age ≥18, absence of neovascular/proliferative disease, qualifying BCVA (≥54 ETDRS letters or ≥20/80 Snellen), and administration by or under the supervision of an ophthalmologist.

"Encelto is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel)."

Sign up to see full coverage criteria, indications, and limitations.